1Noda K, Nishiwaki Y, Kawahara M, et al Irinotecan plus cisplatin comparedwith etoposide plus cisplatin for extensive small-cell lung cancer. N Engl JMed, 2002, 346(2): 85-91.
2Kubota K, Hida T, Ishikura S, et al. Randomized phase III study comparingetoposide and cisplatin (EP) with irinotecan and cisplatin (IP) followingEP plus concurrent accelerated hyperfractionated thoracic radiotherapy(EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC):JCOG0202.J Clin Oncol, 2012,30(suppl): 7028.
3Park K, Sun JM, Kim SW, et al. Phase III trial of concurrent thoracicradiotherapy (TRT) with either the first cycle or the third cycle of cisplatinand etoposide chemotherapy to determine the optimal timing of TRT forlimited-disease small cell lung cancer. J Clin Oncol, 2012, 30(suppl): 7004.
4Shipley D, Hainsworth JD, Mekhail T, et al Amrubicin and carboplatin withpegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI). JClin Oncol, 2012,30(suppl): 7100.
5Kotani Y, Satouchi M, Ando M, et al. A phase III study comparing amrubicinand cisplatin (AP) with irinotecan and cisplatin (IP) for the treatmentof extended-stage small cell lung cancer (ED-SCLC): JCOG0S09. J ClinOncol, 2012, 30(suppl): 7003.
6Ellis PM, Shepherd FA, Laurie SA, et al. NCIC IND. 190: A phase I trial ofMK-0646 in combination with cisplatin and etoposide in extensive-stagesmall cell lung cancer (ES SCLC). J Clin Oncol, 2012, 30(suppl): 7093.
7Wilson JM, Grundy A, Best K, et al. Effect of thoracic radiotherapy inextensive-disease small cell lung cancer on progression-free and overallsurvival: A retrospective review. J Clin Oncol, 2012, 30(suppl): el7519.
8Saito R, Inoue A, Sugawara S, et al Phase II study of amrubicin (AMR)combined with carboplatin (CBDCA) for refractory relapsed small cell lungcancer (SCLC): North Japan Lung Cancer Group 0802. J Clin Oncol, 2012,30(suppl): 7086.
9Koster W, Heider A, Niederle N, et al. Phase II trial with carboplatin andbendamustine in patients with extensive stage small-cell lung cancer. JThorac Oncol, 2007, 2(4): 312-316.
10Lovly CM, Li Cl, Hutchison AS, et al. A phase II study of second-linebendamustine in relapsed or refractory small cell lung cancer (SCLC). J ClinOncol, 2012, 30(suppl): 7094.
